Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

University of British Columbia

$15,000.00

Development of CAR T cell-based immunotherapy for high risk medulloblastoma informed by membrane proteomics

EF 2021-22

Résumé
Brain cancer is the most common pediatric solid cancer, devastating the lives of more than 5.000 children and their families every year. However, current chemoradiotherapy approaches are often ineffective and cause serious side effects on the developing brain, such as permanent seizures and learning disabilities. Thus, more effective and less damaging therapies are urgently needed. Immunotherapy has been recently credentialed as a breakthrough in cancer therapy. During the last 10 years, we have witnessed novel immunotherapy agents approved by the FDA for the treatment of childhood cancer, providing proof-of-principle that immunotherapy can be effective against pediatric cancers resistant to standard chemoradiotherapy. There is every indication that this progress presents the tip of the iceberg and that with continued efforts, effective immunotherapies can be developed for many currently incurable pediatric cancers. The ability for cancers to grow rapidly is in part due to the activation of certain proteins exposed on the membrane of cancer cells. The goal of immunotherapy is to target cells exposing these proteins while sparing normal, healthy cells. Among immunotherapy strategies, chimeric antigen receptor (CAR) T cell therapy exploits the patient's own immune system to fight cancer cells. CAR T cell therapy has achieved promising results in pediatric blood cancers; however, this strategy has not been tested extensively in pediatric brain tumors such as medulloblastoma. A major barrier is that most targets on the surface of cancer cells are currently unknown. In this proposal we will identify new targets for medulloblastoma immunotherapy and develop CAR T cells against them. In addition, we will test the efficacy of newly developed CAR T cells in mice with medulloblastoma. The CAR T cells developed in this project will be directly translatable to the clinic and designed to have a major beneficial impact on the outcome of children affected by medulloblastoma.
Programme
CIHR Fellowship
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
454536
Name
Delaidelli Alberto
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Development of CAR T cell-based immunotherapy for high risk medulloblastoma informed by membrane proteomics
Programtype2
Fellowship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$15,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Pediatric Cancer
Abstract
Brain cancer is the most common pediatric solid cancer, devastating the lives of more than 5.000 children and their families every year. However, current chemoradiotherapy approaches are often ineffective and cause serious side effects on the developing brain, such as permanent seizures and learning disabilities. Thus, more effective and less damaging therapies are urgently needed. Immunotherapy has been recently credentialed as a breakthrough in cancer therapy. During the last 10 years, we have witnessed novel immunotherapy agents approved by the FDA for the treatment of childhood cancer, providing proof-of-principle that immunotherapy can be effective against pediatric cancers resistant to standard chemoradiotherapy. There is every indication that this progress presents the tip of the iceberg and that with continued efforts, effective immunotherapies can be developed for many currently incurable pediatric cancers. The ability for cancers to grow rapidly is in part due to the activation of certain proteins exposed on the membrane of cancer cells. The goal of immunotherapy is to target cells exposing these proteins while sparing normal, healthy cells. Among immunotherapy strategies, chimeric antigen receptor (CAR) T cell therapy exploits the patient's own immune system to fight cancer cells. CAR T cell therapy has achieved promising results in pediatric blood cancers; however, this strategy has not been tested extensively in pediatric brain tumors such as medulloblastoma. A major barrier is that most targets on the surface of cancer cells are currently unknown. In this proposal we will identify new targets for medulloblastoma immunotherapy and develop CAR T cells against them. In addition, we will test the efficacy of newly developed CAR T cells in mice with medulloblastoma. The CAR T cells developed in this project will be directly translatable to the clinic and designed to have a major beneficial impact on the outcome of children affected by medulloblastoma.
Competitiondate
202110
Approvedterm2
0 yr 4 mths
Pinamesdelim
Delaidelli, Alberto
Approvedterm
0 an 4 mois
Cihrcontribution2
~ $15,000~ $0~